Trial reportAddiction science & clinical practice2026
From access to sustainability: understanding telemedicine-based buprenorphine induction through a RE-AIM lens.
Trial report in Addiction science & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTelemedicine-Assisted Buprenorphine Induction (TABI) is a hybrid treatment model combining in-person initiation with remote follow-up, developed to improve access to opioid agonist maintenance treatment (OAMT) in India. While clinical trials demonstrated its non-inferiority to standard care, process evaluations are essential to understand contextual factors influencing its implementation and sustainability.
methodsA qualitative process evaluation, guided by the RE-AIM framework, was conducted alongside a randomized controlled trial comparing TABI with in-person induction. Fourteen patients with opioid use disorder (OUD) who underwent TABI in the previous three months and four TABI providers were interviewed using semi-structured guides. Thematic analysis was conducted iteratively, and data saturation was confirmed at the 14th patient interview. Data were analyzed using the framework method, combining deductive coding based on RE-AIM domains.
resultsTABI improved treatment reach by reducing travel and time barriers, although digital literacy challenges, network instability, and providers' bias for judging clinical suitability might constrain implementation. Participants reported positive outcomes, including reduced opioid use and functional improvements. Adoption was supported by family engagement and provider trust but hindered by stigma and technological barriers. Implementation fidelity was largely maintained, with providers adapting workflows to address connectivity disruptions. Sustainability was linked to structured follow-up, hybrid care reinforcement, and motivational interventions.
conclusionTABI is an acceptable, feasible, and effective model for OAMT delivery in low-resource settings. Future scale-up should address digital inequities, strengthen psychosocial and motivational supports, embed periodic in-person reinforcement, and integrate stigma-reduction strategies to optimize long-term treatment outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.